Literature DB >> 25500312

Dynamic contrast-enhanced perfusion processing for neuroradiologists: model-dependent analysis may not be necessary for determining recurrent high-grade glioma versus treatment effect.

J D Hamilton1, J Lin2, C Ison3, N E Leeds3, E F Jackson4, G N Fuller5, L Ketonen3, A J Kumar3.   

Abstract

BACKGROUND AND
PURPOSE: Dynamic contrast-enhanced perfusion MR imaging has proved useful in determining whether a contrast-enhancing lesion is secondary to recurrent glial tumor or is treatment-related. In this article, we explore the best method for dynamic contrast-enhanced data analysis.
MATERIALS AND METHODS: We retrospectively reviewed 24 patients who met the following conditions: 1) had at least an initial treatment of a glioma, 2) underwent a half-dose contrast agent (0.05-mmol/kg) diagnostic-quality dynamic contrast-enhanced perfusion study for an enhancing lesion, and 3) had a diagnosis by pathology within 30 days of imaging. The dynamic contrast-enhanced data were processed by using model-dependent analysis (nordicICE) using a 2-compartment model and model-independent signal intensity with time. Multiple methods of determining the vascular input function and numerous perfusion parameters were tested in comparison with a pathologic diagnosis.
RESULTS: The best accuracy (88%) with good correlation compared with pathology (P = .005) was obtained by using a novel, model-independent signal-intensity measurement derived from a brief integration beginning after the initial washout and by using the vascular input function from the superior sagittal sinus for normalization. Modeled parameters, such as mean endothelial transfer constant > 0.05 minutes(-1), correlated (P = .002) but did not reach a diagnostic accuracy equivalent to the model-independent parameter.
CONCLUSIONS: A novel model-independent dynamic contrast-enhanced analysis method showed diagnostic equivalency to more complex model-dependent methods. Having a brief integration after the first pass of contrast may diminish the effects of partial volume macroscopic vessels and slow progressive enhancement characteristic of necrosis. The simple modeling is technique- and observer-dependent but is less time-consuming.
© 2015 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25500312      PMCID: PMC7964311          DOI: 10.3174/ajnr.A4190

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  21 in total

1.  Deconvolution analysis of dynamic contrast-enhanced data based on singular value decomposition optimized by generalized cross validation.

Authors:  Kenya Murase; Youichi Yamazaki; Shohei Miyazaki
Journal:  Magn Reson Med Sci       Date:  2004       Impact factor: 2.471

2.  Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI.

Authors:  Steven Sourbron; Michael Ingrisch; Axel Siefert; Maximilian Reiser; Karin Herrmann
Journal:  Magn Reson Med       Date:  2009-07       Impact factor: 4.668

3.  Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.

Authors:  L S Hu; L C Baxter; K A Smith; B G Feuerstein; J P Karis; J M Eschbacher; S W Coons; P Nakaji; R F Yeh; J Debbins; J E Heiserman
Journal:  AJNR Am J Neuroradiol       Date:  2008-12-04       Impact factor: 3.825

Review 4.  New advances that enable identification of glioblastoma recurrence.

Authors:  Isaac Yang; Manish K Aghi
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

5.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

6.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Authors:  Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

7.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.

Authors:  A J Kumar; N E Leeds; G N Fuller; P Van Tassel; M H Maor; R E Sawaya; V A Levin
Journal:  Radiology       Date:  2000-11       Impact factor: 11.105

8.  The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Authors:  Karla V Ballman; Jan C Buckner; Paul D Brown; Caterina Giannini; Patrick J Flynn; Betsy R LaPlant; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2006-11-15       Impact factor: 12.300

9.  Effect of bevacizumab on radiation necrosis of the brain.

Authors:  Javier Gonzalez; Ashok J Kumar; Charles A Conrad; Victor A Levin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-01       Impact factor: 7.038

10.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Authors:  M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

View more
  7 in total

1.  Early imaging marker of progressing glioblastoma: a window of opportunity.

Authors:  Na Tosha N Gatson; Shane P Bross; Yazmin Odia; Gino J Mongelluzzo; Yirui Hu; Laura Lockard; Jesse J Manikowski; Anand Mahadevan; Syed A J Kazmi; Michel Lacroix; Andrew R Conger; Joseph Vadakara; Lakshmi Nayak; T Linda Chi; Minesh P Mehta; Vinay K Puduvalli
Journal:  J Neurooncol       Date:  2020-06-29       Impact factor: 4.130

2.  Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study.

Authors:  J E Park; J Y Kim; H S Kim; W H Shim
Journal:  AJNR Am J Neuroradiol       Date:  2020-10-15       Impact factor: 3.825

Review 3.  MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.

Authors:  Praneil Patel; Hediyeh Baradaran; Diana Delgado; Gulce Askin; Paul Christos; Apostolos John Tsiouris; Ajay Gupta
Journal:  Neuro Oncol       Date:  2016-08-08       Impact factor: 12.300

4.  The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated MGMT Promoter.

Authors:  Y S Choi; S S Ahn; H-J Lee; J H Chang; S-G Kang; E H Kim; S H Kim; S-K Lee
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-22       Impact factor: 3.825

5.  Response prediction of vestibular schwannoma after gamma-knife radiosurgery using pretreatment dynamic contrast-enhanced MRI: a prospective study.

Authors:  Inpyeong Hwang; Seung Hong Choi; Jin Wook Kim; Eung Koo Yeon; Ji Ye Lee; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Ji-Hoon Kim; Chul-Ho Sohn
Journal:  Eur Radiol       Date:  2022-01-27       Impact factor: 5.315

6.  Value of Dynamic Contrast-Enhanced MRI to Detect Local Tumor Recurrence in Primary Head and Neck Cancer Patients.

Authors:  Young Jun Choi; Jeong Hyun Lee; Yu Sub Sung; Ra Gyoung Yoon; Ji Eun Park; Soon Yuhl Nam; Jung Hwan Baek
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

7.  Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: A systematic review and meta-analysis.

Authors:  Sachi Okuchi; Antonio Rojas-Garcia; Agne Ulyte; Ingeborg Lopez; Jurgita Ušinskienė; Martin Lewis; Sara M Hassanein; Eser Sanverdi; Xavier Golay; Stefanie Thust; Jasmina Panovska-Griffiths; Sotirios Bisdas
Journal:  Cancer Med       Date:  2019-08-07       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.